Genomic Health Announces Preliminary Results From A Study Of Oncotype DX(TM) In Node-Positive Breast Cancer Patients

Genomic Health, Inc. (Nasdaq: GHDX) announced encouraging results from a study of Oncotype DX in postmenopausal women with node-positive, hormone receptor positive breast cancer conducted by the Southwest Oncology Group (SWOG), a National Cancer Institute clinical trials cooperative group. [click link for full article]

More: continued here

Filed under: Endocrinology on October 20th, 2007